1. Home
  2. CYTK vs BIO Comparison

CYTK vs BIO Comparison

Compare CYTK & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

SELL

Current Price

$62.30

Market Cap

10.7B

Sector

Health Care

ML Signal

SELL

Logo Bio-Rad Laboratories Inc.

BIO

Bio-Rad Laboratories Inc.

SELL

Current Price

$351.64

Market Cap

10.1B

Sector

Industrials

ML Signal

SELL

Company Overview

Basic Information
Metric
CYTK
BIO
Founded
1997
1952
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
10.1B
IPO Year
2004
1994

Fundamental Metrics

Financial Performance
Metric
CYTK
BIO
Price
$62.30
$351.64
Analyst Decision
Strong Buy
Hold
Analyst Count
23
3
Target Price
$109.40
★ $335.00
AVG Volume (30 Days)
★ 2.0M
229.8K
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 142.61
EPS
★ N/A
N/A
Revenue
$13,368,000.00
★ $2,583,200,000.00
Revenue This Year
$72.63
N/A
Revenue Next Year
$181.06
$2.13
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 0.65
52 Week Low
$54.30
$236.73
52 Week High
$88.31
$396.23

Technical Indicators

Market Signals
Indicator
CYTK
BIO
Relative Strength Index (RSI) 36.80 38.36
Support Level $59.21 $284.88
Resistance Level $67.65 $391.87
Average True Range (ATR) 2.01 12.91
MACD 0.31 -2.15
Stochastic Oscillator 34.67 1.96

Price Performance

Historical Comparison
CYTK
BIO

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: